Novo Nordisk began shipping an oral formulation of semaglutide marketed as a Wegovy pill in the U.S., with pharmacies filling prescriptions immediately. The company announced a tiered pricing approach that could lower insured patients’ copays while setting an out‑of‑pocket cash price for unsubsidized buyers. Clinical data show the highest oral dose produced roughly 16.6% mean weight loss at 64 weeks versus placebo, compared with up to 17.4% for the injectable Wegovy at peak doses. Novo emphasized the potential to reduce access barriers through a pill option and stepwise dosing to manage tolerability. The commercial launch will test whether an oral GLP‑1 can meaningfully broaden patient access and pressure payers and competitors on pricing and coverage policies.